Problems in Hodgkin's disease management

Blood

Volumn 93, Issue 3, 1999, Pages 761-779

  Aisenberg, Alan C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CARMUSTINE; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL TRIAL; FEBRILE NEUTROPENIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; LAPAROTOMY; LUNG TOXICITY; PRIORITY JOURNAL; REVIEW; STOMATITIS;

EID: 0032926542     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.3.761.403a27_761_779     Document Type: Review

References (217)

1. Ries LAG, Miller BA, Hankey BF, Kosary CL, Harras A, Edwards BK (eds): SEER Cancer Statistics Review, 1973-1994, National Cancer Institute. NIH Pub. No. 97-2789. Bethesda, MD, NIH, 1997
2. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics 1998. CA Cancer J Clin 48:6, 1998
3. Glatstein E, Guernsey JM, Rosenberg SA, Kaplan HS: The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer 24:709, 1969
4. Leibenhaut MH, Hoppe RT, Efron S, Halpern J, Nelson T, Rosenberg SA: Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease. J Clin Oncol 7:81, 1989
5. Mauch P, Larson D, Osteen R, Silver B, Yeap B, Canellos G, Weinstein H, Rosenthal D, Pinkus G, Jochelson M, Coleman CN, Hellman S: Prognostic factors for positive surgical staging in patients with Hodgkin's disease. J Clin Oncol 8:257, 1990
6. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860, 1971
7. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA, Tubiana M: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswold Meeting. [published erratum appears in J Clin Oncol 8:1602, 1990.] J Clin Oncol 7:1630, 1989
8. Gobbi PG, Cavelli C, Gendarini A, Crema A, Ricevuti G, Federico M, Di Prisco U, Ascari E: Revaluation of prognostic symptoms in Hodgkin's disease. Cancer 56:2874, 1985
9. Hoppe RT, Coleman CN, Rosenberg SA, Kaplan HS: The management of stage I-II Hodgkin's disease with irradiation alone or combined modality treatment: The Stanford experience. Blood 59:455, 1982
10. Gilbert R: Radiotherapy in Hodgkin's disease (malignant lymphogranulomatosis). Am J Roentgenol 41:198, 1939
11. Peters MV: A study of survival in Hodgkin's disease treated radiologically. Am J Roentgenol 63:299, 1950
12. Kaplan HS: The radical radiotherapy of regionally localized Hodgkin's disease. Radiology 78:553, 1962
13. DeVita VT, Sepick AA, Carbone PP: Combination chemotherapy for advanced Hodgkin's disease. Ann Intern Med 73:881, 1970
14. Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C: Combination chemotherapy of Hodgkin's disease with Adriamycin, bleomycin, vinblastine and imadazole carboxamide versus MOPP. Cancer 252, 1975
15. Mendenhall NP: Diagnostic procedures and guidlines for the evaluation and follow-up of Hodgkin's disease. Semin Radiat Oncol 6:131, 1996
16. Salloum E, Brandt DS, Caride VJ, Zelteram D, Schubert W, Mannino T, Cooper DL: Gallium scan in the management of patients with Hodgkin's disease. A study of 101 patients. J Clin Oncol 15:518, 1997
17. Altehoefer C, Blum U, Bathmann J, Wustenberg C, Uhrmeister J, Lange W, Schwarzkopf J, Moser E, Langer M: Comparative diagnostic accuracy of magnetic resonance imaging and immunoscintigraphy for detection of bone marrow involvement in patients with malignant lymphoma. J Clin Oncol 15:1754, 1997
18. de Wit M, Baumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK: Whole-body positron emission tomography for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8:S57, 1997 (suppl 1)
19. Moog F, Bangerter M, Diederichs CG, Guhlmann A, Kotzerke J, Merkle E, Kolokythas O, Herrmann F, Reske SN: Lymphoma: Role of whole body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 203:795, 1997
20. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H-K, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA: A revised European-American classification of malignant lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 84:1361, 1994
21. Ferry JA, Harris NL: The pathology of Hodgkin's disease: What's new? Semin Radiat Oncol 6:121, 1996
22. Sextro M, Diehl V, Franklin J, Handsmann H-L, Agnagostopoulos I, Marafioti T, Stein H: Lymphocyte predominant Hodgkin's disease: A workshop report. European Task Force on Lymphoma. Ann Oncol 7:S61, 1996 (suppl 4)
23. Bodis S, Kraus MD, Pinkus G, Silver B, Kadin ME, Canellos GP, Shulman LN, Tarbell NJ, Mauch PM: Clinical presentation and outcome in lymphocyte predominant Hodgkin's disease. J Clin Oncol 15:3060, 1997
24. Zinzani PL, Benandi M, Martelli M, Falini B, Sabattini E, Amadori S, Gherlinzoni F, Martelli MF, Mandelli F, Tura S, Pileri S: Anaplastic large-cell lymphoma: Clinical and prognostic evaluation in 90 adult patients. J Clin Oncol 14:955, 1996
25. Longo DL, Glatstein E, Duffey PL, Young RC, Hubbard SM, Urba WJ, Wesley MN, Raubitschek A, Jaffe ES, Wiernik PH, DeVita VT Jr: Radiation therapy versus combination chemotherapy in the treatment of early stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J Clin Oncol 9:906, 1991
26. Biti GP, Cimino G, Cartoni C, Mangini SM, Anselmo AP, Maurizi Enrici RM, Bellisi GP, Bosi A, Papa A, Giannarelli D, Ponticelli P, Papi MGH, Rossi Ferrini PL, Biagini C, Mandelli F: Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin's disease: Eight-year update of an Italian prospective randomized trial. J Clin Oncol 10:378, 1992
27. Specht L, Gray RG, Clarke MJ, and Peto R for the International Hodgkin's Disease Collaborative Group: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcone of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients. J Clin Oncol 16:830, 1998
28. Vijayakumar S, Myrianthopoulos LC: An updated dose-response analysis of Hodgkin's disease. Radiother Oncol 24:1, 1992
29. Brinker H, Bentzen SM: A re-analysis of available dose-response and time-dose data in Hodgkin's disease. Radiother Oncol 30:227, 1994
30. Gospodorowicz MK, Sutcliffe SB, Clark RM, Dembo AJ, Fitzpatrick PJ, Munro AJ, Bergsagel DE, Patterson BJ, Tsang R, Chua T, Bush RS: Analysis of suprsdiaphragmatic clinical stage I and II Hodgkin's disease treated with radiation alone. Int J Radiat Oncol Biol Phys 22:859, 1992
31. Mauch PM: Management of early stage Hodgkin's disease: The role of radiation therapy and/or chemotherapy. Ann Oncol 7:S79, 1996 (suppl 4)
32. Hoppe RT: Radiation therapy in the management of Hodgkin's disease. Semin Oncol 17:704, 1990
33. Sutcliffe SB, Gospodarowicz MK, Bergsagel DE, Bush RS, Alison RE, Bean HA, Brown TC, Chua T, Clark RM, Curtis JE, Dembo AJ, Fitzpatrick PJ, Hasselback RH, Rideout DF, Sturgeon JFG, Quirt I, Yeoh L, Peters MV: Prognostic groups for management of localized Hodgkin's disease. J Clin Oncol 393, 1985
34. Carde P, Hagenbeek A, Hayat M, Monconduit M, Thomas J, Burgers MJV, Noordijk EM, Tanguy A, Meervaldt JH, Le Fur R, Somers R, Kluin-Nelemans HC, Busson A, Breed WP, Bron D, Holdrinet A, Rutten EHJM, Michiels JJ, Regnier R, Debusscher L, Musella R, Fargeot P, Thyss A, Cattan A, Rigol-Huguet F, Roth S, Caillou B, Dupouy N, Henry-Amar M: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials for the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258, 1993
35. Specht L: Prognostic factors in Hodgkin's disease. Semin Radiat Oncol 6:141, 1996
36. Jones E, Mauch P: Limited radiation therapy for selected patients with pathological stage IA and IIA Hodgkin's disease. Semin Radiat Oncol 6:161, 1996
37. Hagenbeek A, Carde P, Noordijk E, Thomas J, Tirelli U, Misconduit M, Eghbali H, Mandard AM, Henry-Amar M: Prognostic factor tailored treatment of early stage Hodgkin's disease. Results of a prospective randomized Stage III clinical trial in 762 patients (H7 study). Blood 90:565a, 1997 (abstr, suppl 1)
38. Ganesan T, Wrigley P, Murray P, Stansfield AG, d'Ardenne AJ, Arnott S, Jones A, Shant WS, Malpas JS, Lister TA: Radiotherapy for stage I Hodgkin's disease. 20 years experience at St Bartholomew's Hospital. Br J Cancer 3:314, 1990
39. Crnkovich MJ, Leopold K, Hoppe RT, Mauch PM: Stage IB to IIB Hodgkin's disease: The combined experience at Stanford University and the Joint Center for Radiation Therapy. J Clin Oncol 5:1041, 1987
40. Mauch P, Tarbell N, Weinstein H, Silver B, Goffman T, Osteen R, Zajac A, Coleman C, Canellos G, Rosenthal D: Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 6:1576, 1988
41. Specht L, Nordentoft A, Cold S, Clausen N, Nissen N: Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 61:1719, 1988
42. Cosset JM, Henry-Amar M, Meervaldt JH, Carde P, Noordijk EM, Thomas J, Burgers JMV, Somers R, Hayat M, Tubiana M, on behalf of the EORTC Lymphoma Cooperative Group: The EORTC trials for limited stage Hodgkin's disease. Eur J Cancer 28A: 1847, 1992
43. Mauch PM: Controversies in the management of early stage Hodgkin's disease. Blood 83:319, 1994
44. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478, 1992
45. Prosnitz LR, Curtis AM, Knowlton AH, Peters LM, Farber LR: Supradiaphragmatic Hodgkin's disease: Significance of large mediastinal masses. Int J Radiat Oncol Biol Phys 6:809, 1980
46. Longo DL, Russo A, Duffey PL, Hubbard SM, Glatstein E, Hill JB, Jaffe E, Young RS, DeVita VT: Treatment of advanced stage massive mediastinal Hodgkin's disease: The cases for combined modality treatment. J Clin Oncol 9:227, 1991
47. Behar RA, Homing SJ, Hoppe RT: Hodgkin's disease with bulky mediastinal involvement: Effective management with combined modality therapy. Int J Radiat Oncol Biol Phys 25:771, 1993
48. Santoro A, Bonfante V, Viviani S, Devizzi L, Zanini M, Soncini F, Gaaspanini M, Valagussa P, Bonadonna G: Subtotal nodal versus involved field irradiation after 4 cycles of ABVD in early stage Hodgkin's disease. Proc Am Soc Clin Oncol 15:415, 1996 (abstr)
49. Horning SJ, Rosenberg SA, Hoppe RT: Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin's disease: An update. Ann Oncol 7:S105, 1996 (suppl 4)
50. Klasa RJ, Connors JM, Fairey R, Gascoyne R, Hoskin's P, O'Reilly S, Shenkier T, Voss N, Wilson K: Treatment of early stage Hodgkin's disease: Improved outcome with brief chemotherapy and radiotherapy without staging laparotomy. Ann Oncol 7:S21, 1996 (abstr, suppl 3)
51. Horning SJ, Hoppe RT, Mason J, Brown BW, Hancock SL, Baer D, Rosenberg SA: Stanford-Kaiser Permanente G1 study for clinical stage I and IIA Hodgkin's disease: Subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 15:1736, 1997
52. DeVita VT Jr, Serpick A: Combination chemotherapy in the treatment of Hodgkin's disease. Proc Am Assoc Cancer Res 8:13, 1967 (abstr)
53. Longo DL, Young RC, Wesley M, Hubbard AM, Duffey PL, Jaffe ES, DeVita VT Jr: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295, 1986
54. Canellos GP: Is ABVD the standard regimen for Hodgkin's disease based on randomized CALGB comparison of MOPP, ABVD and MOPP alternating with ABVD? Leukemia 10:868, 1996 (suppl 2)
55. Bonadonna G, Valagussa P, Santoro A: Alternating non-cross-resistant combination chemotherapy or MOPP in Stage IV Hodgkin's disease. Ann Intern Med 104:739, 1986
56. Somers R, Corde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, De Pauw BE, Breed WPM, Verdonck L, Burgers JMV, Eghbali H, Zittoun R: A randomized study in Stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alternation of MOPP with ABVD: A European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol 12:279, 1994
57. Connors JM, Klimo P, Adams G, Bums BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B: Treatment of advanced Hodgkin's disease with chemotherapy - Comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: A report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 15:1638, 1997
58. Glick JH, Young ML, Harrington D, Schilsky RL, Beck T, Neiman R, Fisher RI, Peterson BA, Oken MM: MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: The 8-years results of the Intergroup trial. J Clin Oncol 16:19, 1998
59. Hancock BW, Vaughan Hudson G, Vaughn Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC: LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: Results of a British National Lymphoma Investigation trial. J Clin Oncol 10:1252, 1992
60. Gobbi PG, Pieresca C, Ghirardelli ML, Di Renzo N, Federico M, Merli F, Iannitto E, Pitini V, Grignani G, Donelli A, Carotenuto M, Silingardi V, Ascari E: Long-term results of MOPPEBVCAD chemotherapy with optional limited radiotherapy in advanced Hodgkin's disease. Blood 91:2704, 1998
61. Radford JA, Crowther D, Rohatiner AZS, Ryder WDJ, Gupta RK, Oza A, Deakin DP, Arnott S, Wilkinson PM, James RD, Johnson RJ, Lister TA: Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, Ch1VPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol 13:2379, 1995
62. Duggan D, Petroni G, Johnson J, Hanson K, Glick J, Connors R, Chemy R, Barcos M, Peterson BA for CALBG: MOPP/ABV versus ABVD for advanced Hodgkin's disease - A preliminary report of CALBG 8952 (with SWOG, ECOG, NCIC). Proc Am Soc Clin Oncol 16:12a, 1997 (abstr)
63. Viviani V, Bonadonna G, Santoro A, Bonafante V, Zanini M, Devizzi L, Soncini F, Valagussa P: Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: Ten-year results. J Clin Oncol 14:1421, 1996
64. Hasenclever D, Loeffler M, Diehl V, for the German Hodgkin's Lymphoma Study Group: Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. Ann Oncol 7:S95, 1996 (suppl 4)
65. Reuss K, Enger A, Tesch H, Diehl V: Current clinical trials in Hodgkin's disease. Ann Oncol 7:S109, 1996 (suppl 4)
66. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, Loeffler M, Lieberz D, Koch P, Adler M, Tesch H for the German Hodgkin's Lymphoma Study Group: BEACOPP: An intensified chemotherapy regimen in advanced Hodgkin's disease. Ann Oncol 8:143, 1997
67. Frei E III, Luce JK, Gamble G, Coltman CA Jr, Constanzi JJ, Talley RW, Monto RW, Wilson HE, Hewlett JS, Delaney FC, Gehan EA: Combination chemotherapy in advanced Hodgkin's disease: Induction and maintenance of remission. Ann Intern Med 79:376, 1973
68. Young RC, Canellos GP, Chabner BA, Hubbard SM, DeVita VT: Patterns of relapse in advanced Hodgkin's disease. Cancer 42:1001, 1978
69. Prosnitz LR, Farber LR, Kapp DS, Scott J, Bertino JR, Fischer JJ, Cadmen EC: Combined modality therapy for advanced stage Hodgkin's disease: 15-year follow-up data. J Clin Oncol 6:603, 1988
70. Yahalom J, Ryu J, Straus DJ, Gaynor JJ, Meyers J, Caravelli J, Clarkson BD, Fuks Z: Impact of adjuvant radiation on the patterns and rate of relapse in advanced-stage Hodgkin's disease treated with alternating chemotherapy combinations. J Clin Oncol 9:2193, 1991
71. Santoro A, Bonadonna G, Valagussa P, Zucali R, Viviani S, Villani F, Pagnani AM, Bonafante V, Musumeci R, Crippa F, Tess JDT, Banfi A: Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 5:27, 1987
72. Bonadonna G: Modern treatment of Hodgkin's disease: A multidisciplinary approach? Ann Oncol 5:S5, 1994 (suppl 3)
73. Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA Jr, Fisher R: Low-dose involved field radiation after chemotherapy in advanced Hodgkin's disease. Ann Intern Med 120:903, 1994
74. Raemaekers J, Burgers M, Henry-Amar M, Pinna A, Mandard A, Monfardini S, Hagenbeek A, Breed W, Carde P, Vovk M, van Hoof A, Thomas J, Noordijk E, for the EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie: Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: Interim results from the ongoing EORTC-LCC and GPMC phase III trial. Ann Oncol 8:S111, 1997 (suppl 1)
75. Longo DL: The case against the routine use of radiation therapy in advanced stage Hodgkin's disease. Cancer Invest 14:353, 1996
76. Prosnitz LR, Wu JJ, Yahalom J: The case for adjuvant radiation therapy in advanced Hodgkin's disease. Cancer Invest 14:361, 1996
77. Doria R, Holford T, Farber LR, Prosnitz LR, Cooper DL: Second solid malignancies after combined modality therapy of Hodgkin's disease. J Clin Oncol 13:2016, 1995
78. Loeffler M, Diehl V, Pfreundschuh M, for the German Hodgkin's Lymphoma Study Group: Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease. J Clin Oncol 15:2275, 1997
79. Glick J, Rubin P, Tsiatis A, Graves R, Bennett J: Hodgkin's disease stage IIB & IV: Failure of radiation consolidation to improve survival compared to B-MOPP-ABVD: An ECOG study. Int J Radiat Oncol Biol Phys 13:91, 1987 (abstr, suppl 1)
80. Glick J, Tsiatis A, Chen M, Rassiga A, Mann R, O'Connell M: Improved survival with MOPP-ABVD compared to BCVPP ± radiotherapy (RT) for advanced Hodgkin's disease: 6-year ECOG results. Blood 76:350a, 1990 (abstr, suppl 1)
81. Pavlovsky S, Santarelli MT, Sackmann F, Muriel I, Fernandez I, Garcia I, Schwartz L, Montero C, Lobo Sanahuja F, Magnasco H, Costa A, Corrado C, Rana R, Bezares R: Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV Hodgkin's disease. Ann Oncol 3:533, 1992
82. Brizel DM, Winer EP, Prosnitz LR, Scott J, Crawford J, Moore JO, Gockerman JP: Improved survival in advanced Hodgkin's disease. Int J Radiat Oncol Biol Phys 19:535, 1990
83. Yelle Y, Bergsagel D, Basco V, Brown T, Bush R, Gillies J, Israels L, Miller A, Rideout D, Whitelaw D, Willan A, Pater J: Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial. J Clin Oncol 9:1983, 1991
84. Loeffler M, Hasenclever D, Sextro M, Assouline D, Bartolucci AA, Cassileth PA, Diehl V. Fisher RI, Hoppe RT, Jacobs P, Pater JL, Pavlovsky S, Thompson E, Wiernik P, for the International Database on Hodgkin's Disease Overview Study Group: Meta-analysis of chemotherapy versus combined treatment trials in Hodgkin's disease. J Clin Oncol 16:818, 1998
85. Yuen AR, Horning SJ: Hodgkin's disease: Management of first relapse. Oncology 10:233, 1996
86. Roach M III, Brophy N, Varghese A, Hoppe RT: Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 8:623, 1990
87. Healey EA, Tarbell NJ, Kalish LA, Silver B, Rosenthal DS, Marcus K, Shulman LN, Coleman CN, Canellos G, Weinstein H, Mauch P: Prognostic factors for patients with Hodgkin's disease in first relapse. Cancer 71:2613, 1993
88. Specht L, Horwich A, Ashley S: Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report for the International Database on Hodgkin's Disease. Int J Radiat Oncol Biol Phys 30:805, 1994
89. Santoro A, Viviani S, Villarreal CJR, Bonofante V, Delfino A, Valagussa P, Bonadonna G: Salvage chemotherapy in Hodgkin's disease irradiation failure: Superiority of doxorubicin-containing regimens over MOPP. Cancer Treat Rep 70:343, 1986
90. Fisher RI, DeVita VT Jr, Hubbard SP, Simon R, Young RC: Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med 90:761, 1979
91. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E, Phares JC, Jaffe ES, Urba WJ, DeVita VT Jr: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability of cure. J Clin Oncol 10:21, 1992
92. Bonadonna G, Santoro A, Gianni AM, Viviani S, Siena S, Bregni M, Zucali R, Lombardi F, Bonafanti V, Gianni L: Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Ann Oncol 1:9, 1991
93. Viviani S, Santoro A, Negretti E, Bonafanti V, Valagussa P, Bonadonna G: Salvage chemotherapy in Hodgkin's disease: Results in patients relapsing more than twelve months after complete remission. Ann Oncol 1:123, 1990
94. Harker WG, Kushlan P, Rosenberg SA: Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP:ABVD and B-CAVe. Ann Intern Med 101:440, 1984
95. Tannir N, Hagemeister F, Velasquez W, Cabanillas F: Long term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 1:423, 1983
96. Bonefante V, Santoro A, Viviani S, Devizzi S, Balzarotti M, Soncini F, Zanini M, Valagussa P, Bonadonna G: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. Ann Clin Oncol 15:528, 1997
97. Lohri A, Barnett M, Fairey RN, O'Reilly SE, Phillips GL, Reece D, Voss N, Connors JM: Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience. Blood 77:2292, 1991
98. Brice P, Bastion Y, Divine M, Nedellec G, Ferrant A, Gabarre J, Reman O, Lepage E, Ferme C: Analysis of prognostic factors after the first relapse of Hodgkin's disease in 187 patients. Cancer 78:1293, 1996
99. Tourani J-M, Levy R, Colonna P, Desablens B, Leprise P-Y, Guilhot F, Brahimi SB, Belhani M, Ifrah N, Sensebe L, Lemevel A, Lotz J-P, Le Maignan C, Andrieu J-M: High-dose salvage chemotherapy without bone marrow transplantation for adult patients with refractory Hodgkin's disease. J Clin Oncol 10:1096, 1992
100. Pfreundschuh MG, Rueffer U, Lathan B, Schmitz N, Brosteanu O, Hasenclever D, Haas R, Kirchner H, Koch P, Kuse R, Loeffler M, Diehl V: Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: A trial of the German Hodgkin's Disease Study Group. J Clin Oncol 12:580, 1994
101. Diehl LF, Perry DJ, Terebelo P, Baldwin PE, Hurwitz M, Kimball DB, Dorn RV: Radiation as salvage therapy for patients with Hodgkin's disease relapsing after MOPP (mechorethamine, vincristine, prednisone and procarbazine) chemotherapy. Cancer Treat Rep 67:27, 1983
102. Roach M III, Kapp DS, Rosenberg SA, Hoppe RT: Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol 5:550, 1987
103. Uematsu M, Tarbell NJ, Silver B, Coleman NS, Rosenthal DS, Shulman LN, Canellos G, Weinstein H, Mauch P: Wide-field radiation therapy with or without chemotherapy for patients with Hodgkin's disease in relapse after initial combination chemotherapy. Cancer 72:207, 1993
104. Fox KA, Lippman SM, Cassady JR, Heusinveld RS, Miller TP: Radiation therapy salvage of Hodgkin's disease following chemotherapy failure. J Clin Oncol 5:38, 1987
105. Pezner RD, Lipsett JA, Vora N, Forman SJ: Radical radiotherapy as salvage treatment for relapse of Hodgkin's disease initially treated by chemotherapy alone: Prognostic significance of the disease-free interval. Int J Radiat Oncol Biol Phys 30:965, 1994
106. Goldstone AH, McMillan AK: The place of high-dose therapy with haemopoietic stem cell transplanation in relapsed and refractory Hodgkin's disease. Ann Oncol 4:S21, 1993 (suppl 1)
107. Phillips GL, Wolff SN, Herzig RH, Lazarus HM, Fay JW, Lin H-S, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig GP: Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 73:2086, 1989
108. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137, 1993
109. Bierman PJ, Bagin RG, Jagannath S, Vose JM, Spitzer G, Kessinger A, Dicke KA, Armitage JO: High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Long term follow-up in 128 patients. Ann Oncol 4:767, 1993
110. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW, Wong RM, Brown BW, Blume KG: High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89:801, 1997
111. Crump M, Smith AM, Brandwein J, Couture F, Sherret H, Sutton DMC, Scott JG, McCrae J, Murray C, Pantalony D, Sutcliffe SB, Keating A: High-dose etoposide and melphalan and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: Importance of disease status at transplant. J Clin Oncol 11:704, 1993
112. Reece DE, Barnett JD, Shepherd JD, Klasa RJ, Nantel SH, Sutherland HJ, Klingemann HG, Fairey RN, Voss NJ, Connors JM, O'Reilly SE, Spinelli JJ, Phillips GL: High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with and without cisplatin (CBV ± P) and autologous transplantation for patients with Hodgkin's disease who fail to enter complete remission after combination chemotherapy. Blood 86:451, 1995
113. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann H-G, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan K-W, Phillips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83:1193, 1994
114. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS, Smith EP, Molina A, Stepam DE, Somlo G, Margolin KA, Sniecinski I, Dagis AC, Niland J, Pezner R, Forman SJ: High-dose chemotherapy with and without total body irradiation followed by autologous bone marrow and/or peripheral stem cell transplantation for patients with relapsed or refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 85:1381, 1995
115. Chao NJ, Kastrissios H, Long GD, Negrin RS, Horning SJ, Wong RM, Blaschke TF, Blume KG: A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 75:1354, 1995
116. Forman SJ: Role of high-dose therapy and stem-cell transplantation in the management of Hodgkin's disease. Alexandria, VA, American Association of Clinical Oncology Educational Book, 33rd Annual Meeting, Denver, CO, May 17-20, 1997, p 244
117. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sander JE, Bensinger WI, Martin PJ, Storb R, Sullivan KM, Hansen JA, Thomas ED: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 11:2342, 1993
118. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH, for the European Group for Blood and Marrow Transplantation: Autologous bone marrow transplantation is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 14:1291, 1996
119. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL Jr, Pavlovsky S, Petersen FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM: Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14:57, 1996
120. Mundt AJ, Sibley G, Williams S, Hallahan D, Nautiyal J, Weichelsbaum RR: Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease. Int J Radiat Oncol Biol Phys 33:261, 1995
121. O'Brien MER, Milan S, Cunningham D, Jones AL, Nicolson P, Hickish T, Hill M, Gore ME, Viner C: High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease - A pragmatic prognostic index. Br J Cancer 73:1272, 1996
122. Desch CE, Lasala MR, Smith TJ, Hillner BE: The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after chemotherapy relapse. J Clin Oncol 10:200, 1992
123. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, Chopra R, Milligan D, Vaughan Hudson G: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomized trial. Lancet 341:1051, 1993
124. Yuen AR, Rosenberg SA, Hoppe RT, Halpern JD, Horning SJ: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814, 1997
125. Darrington DL, Vose JM, Anderson JA, Bierman PJ, Bishop MR, Chan WC, Morris ME, Reed EC, Sanger WG, Tarantolo SR, Weisenberger DD, Kessinger A, Armitage JO: Incidence and characterization of secondary myeodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527, 1994
126. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe S, Aster JC, Leavitt P, Mauch P, Freedman AS, Nadler LM: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535, 1994
127. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf DJ: Myelodysplastic syndrome after autologous bone marrow transplantation: An additional late complication of curative cancer therapy. Blood 83:3780, 1994
128. Traweek ST, Slovak ML, Nademanee A, Brynes RK, Niland JC, Forman SJ: Clonal karyotypic hematopoietic cell abnormalities occurring after autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Blood 84:957, 1994
129. Rohatiner A, Myelodysplasia and acute myelogenous leukemia after myeloablative therapy with autologous stem-cell transplantation. J Clin Oncol 12:2521, 1994
130. Socie G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, Gluckman E: Malignancies occurring after the treatment for aplastic anemia: A survey on 1680 patients conducted by the European Group for Bone Marrow Transplantation (EBMT)-Severe Aplastic Anemia Working Party. Blood 80:169a, 1992 (abstr, suppl 1)
131. Chao NJ, Nademanee AP, Long GD, Schmidt GM, Donlon TA, Parker P, Slovak ML, Nagasawa LS, Blume KG, Forman SJ: Importance of bone marrow cytogenetic evaluation before bone marrow transplantation for Hodgkin's disease. J Clin Oncol 9:1575, 1991
132. Mendenhall NP, Noyes WD, Million RR: Total body irradiation for stage II-IV non-Hodgkin's lymphoma: Ten-year follow-up. J Clin Oncol 7:67, 1989
133. Travis LB, Weeks J, Curtis RE, Chaffey JT, Stovall M, Banks PM, Boyce JD Jr: Leukemia following low-dose total body irradiation and chemotherapy for non-Hodgkin's lymphoma. J Clin Oncol 14:565, 1996
134. Bhatia S, Ramsay NKC, Steinbuch M, Dusenberry KE, Shapiro RS, Weisdorf DJ, Robison LL, Miller JS, Neglia JP: Malignant neoplasms following bone marrow transplantation. Blood 87:3633, 1996
135. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socie G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF Jr, Boyce JD Jr: Solid cancers after bone marrow transplantation. N Engl J Med 336:897, 1997
136. Carde P: Who are the high-risk patients with Hodgkin's disease? Leukemia 10:S62, 1996 (suppl 2)
137. Lee SM, Radford JA, Ryder WDJ, Collins CD, Deakin DP, Crowther D: Prognostic factors for disease progression in advanced Hodgkin's disease: An analysis of patients aged 60 years and younger showing no progression in the first 6 months after starting chemotherapy. Br J Cancer 75:110, 1997
138. Hasenclever D, Diehl V, for the International Prognostic Factors Project for Advanced Hodgkin's Disease: A prognostic score for advanced Hodgkin's disease. N Engl J Med 339:1506, 1998
139. Carella AM: The place of high-dose therapy with autologous stem cell transplantation in primary treatment of Hodgkin's disease. Ann Oncol 4:S15, 1993 (suppl 1)
140. Gianni AM, Siena S, Bregni M, Lombardi F, Gandola L, DiNicola M, Magni M, Peccatori F, Valagussa P, Bonnadonna G: High-dose sequential chemotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease - A 6-year update. Ann Oncol 4:889, 1993
141. Hoppe RT: Hodgkin's disease: Complications of therapy and excess mortality. Ann Oncol 8:S115, 1997 (suppl 1)
142. Mauch PM, Kalish LA, Marcus KC, Shulman LN, Krill E, Tarbell NJ, Silver B, Weinstein H, Come S, Canellos GP, Coleman CN: Long-term survival in Hodgkin's disease: Relative impact of mortality, second tumors, infection and cardiovascular disease. Cancer J Sci Am 1:33, 1995
143. Kaldor JM, Day NE, Band P, Choi NW, Clarke EA, Coleman NP. Hakama M, Koch M, Langmark F, Neal FE, Pettersson F, Pompe-Kirn V, Prior P, Storm HH: Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: An international collaborative study among cancer registries. Int J Cancer 39:571, 1987
144. Somers R, Henry-Amar M, Meerwaldt JT, Carde P: Treatment strategy in Hodgkin's disease. Colloque INSERM/John Libbey Eurotext Ltd 196:357, 1990
145. Henry-Amar M: Second cancer after the treatment of Hodgkin's disease: A report from the International Database on Hodgkin's Disease: Ann Oncol 3:S117, 1992 (suppl 4)
146. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, Bennett MH, MacLennan KA: Risk of second primary cancers after Hodgkin's disease by type of treatment: Analysis of 2846 patients in the British National Lymphoma Investigation. Br Med J 304:1137, 1992
147. Biti G, Cellai E, Magrini SM, Papi MG, Ponticelli P, Boddi V: Second solid tumors and leukemias after treatment for Hodgkin's disease: An analysis of 1121 patients from a single institution. Int J Radiat Oncol Biol Phys 29:25, 1994
148. Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EHM, van Heerde P, Somer R: Second cancer risk following Hodgkin's disease: A 20-year follow-up study. J Clin Oncol 12:312, 1994
149. Pedersen-Bjergaard J, Larsen SO: Incidence of acute nonlymphocytic leukemia, preleukemia and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease. N Engl J Med 307:965, 1982
150. Kaldor JM, Day NE, Clarke A, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, Bell J, Pedersen D, Band P, Assouline D, Koch M, Choi W, Prior P, Blair V, Langmark F, Kirn VP, Neal F, Peters D, Pfeiffer R, Karjalainen S, Cuzick J, Sutcliffe SB, Somers R, Pellae-Cosset B, Papagallo GL, Fraser P, Storm H, Stovall M: Leukemia following Hodgkin's disease. N Engl J Med 322:7, 1990
151. Kantarjian HM, Keating MJ: Therapy-related leukemia and myelodysplastic syndromes. Semin Oncol 14:435, 1987
152. O'Donnell MR, Long GD, Parker PM, Niland J, Nademanee A, Amylon M, Chao N, Negrin RS, Schmidt GM, Slovak ML, Smith EP, Snyder DS, Stein AS, Traweek T, Blume KG, Forman SJ: Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol 13:2973, 1995
153. Sugar M, Buckner CD, Applebaum FR, Stewart P, Deeg HJ, Weiden PL, Sullivan KM, Fefer A, Thomas ED: Marrow transplantation for acute nonlymphocytic leukemia following therapy for Hodgkin's disease. J Clin Oncol 5:731, 1987
154. Van Leeuwen FE, Chorus AMJ, van den Belt-Dusebout AW, Hagenbeek A, Noyon R, van Kerkhoff EHM, Pinedo HM, Somers R: Leukemia risk following Hodgkin's disease: Relation to cumulative dose of alkylating agents, treatment with teniposide combinations, and bone marrow damage. J Clin Oncol 12:1063, 1994
155. Van Leeuwen FE: Adverse effects of treatment: Second cancers, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1997, p 2773
156. Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA: Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 318:76, 1988
157. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows AT: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 334:745, 1996
158. Valagussa P, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G: Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4:830, 1986
159. Valagussa P, Bonadonna G: Carcinogenic effects of cancer treatment, in Peckham M, Pinedo H, Veronesi U (eds): Oxford Textbook of Oncology. Oxford, UK, Oxford University Press, 1995, p 2348
160. Tester WJ, Kinsella TJ, Waller B, Makuch RW, Kelley PA, Glatstein E, DeVita VT: Second malignant neoplasms complicating Hodgkin's disease: The National Cancer Institute experience. J Clin Oncol 2:762, 1984
161. Young RC, Bookman MA, Longo DL: Late complications of Hodgkin's disease. J Natl Cancer Inst Monogr 10:55, 1990
162. Cimino G, Papa G, Tura S, Mazza P, Rossi Ferrini PL, Bosi A, Amadori S, Lo Coco F, D'Arcangelo E, Giannarelli D, Mandelli F: Second primary cancer following Hodgkin's disease: Updated result of an Italian multicentric study. J Clin Oncol 9:432, 1991
163. Mauch PM, Canellos GP, Rosenthal DS, Hellman S: Reduction in fatal complications from combined mortality therapy of Hodgkin's disease. J Clin Oncol 3:501, 1985
164. Andrieu J-M, Ifrah N, Payen C, Fermanian J, Coscas Y, Flandrin G: Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy of Hodgkin's disease. J Clin Oncol 8:1148, 1990
165. Tura S, Fiacchini M, Zinzani PL, Brusamolino E, Gobbi PG: Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. J Clin Oncol 11:925, 1993
166. Winick NJ, McKenna RW, Shuster JJ, Schneider NR, Borowitz MJ, Bowman WP, Jacaruso D, Kamen BA, Buchanan GR: Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 11:209, 1993
167. Krikorian JG, Burke JS, Rosenberg SA, Kaplan HS: Occurrence of non-Hodgkin's lymphoma after therapy for Hodgkin's disease. N Engl J Med 300:452, 1979
168. Zarrabi MH, Rosner F: Second neoplasms in Hodgkin's disease: Current controversies. Hematol Oncol Clin North Am 3:303, 1989
169. Tucker MA: Solid second cancers following Hodgkin's disease. Hematol Oncol Clin North Am 7:389, 1993
170. Hancock SL, Tucker MA, Hoppe RT: Breast cancer after Hodgkin's disease treatment. J Natl Cancer Inst 85:25, 1993
171. Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT: Gastrointestinal cancer after treatment of Hodgkin's disease. Int J Radiat Oncol Biol Phys 37:67, 1997
172. Jacquillat C, Khayat D, Desprez-Curely JP, Weil M, Brocheriou C, Auclerc G, Chamseddine N, Bernard J: Non-Hodgkin's lymphoma occurring after Hodgkin's disease: Four new cases and a review of the literature. Cancer 53:459, 1984
173. Aisenberg AC: Coherent view of non-Hodgkin's lymphoma. J Clin Oncol 13:2656, 1995
174. Gaidano G, Dalla-Favera R: Lymphoma: Molecular biology, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 5). Philadelphia, PA, Lippincott, 1997, p 2131
175. Wickert RS, Weisenberger DD, Tierens A, Greiner TC, Chan WC; Clonal relationship between lymphocytic predominance Hodgkin's disease and concurrent or subsequent large-cell lymphoma of B lineage. Blood 86:2312, 1995
176. Louie S, Daoust PR, Schwartz RS: Immunodeficiency and the pathogenesis of non-Hodgkin's lymphoma. Semin Oncol 7:267, 1980
177. List AF, Greco FA, Vogler LB: Lymphoproliferative diseases in immunocompromised hosts: The role of Epstein-Barr virus. J Clin Oncol 5:1673, 1987
178. Filipovich AH, Heinitz KJ, Robison LL, Frizzera G: The Immunodeficiency Cancer Registry: A research resource. Am J Ped Hematol Oncol 9:183, 1987
179. Penn I: Cancers complicating organ transplantation. N Engl J Med 323:1767, 1990
180. Ferry JA, Harris NL: Atlas of Lymphoid Hyperplasia and Lymphoma. Philadelphia, PA, Saunders, 1997, p 214
181. Salloum E, Tallini G, Levy A, Cooper DL: Burkitt's lymphoma-leukemia in patients treated for Hodgkin's disease. Cancer Invest 14:527, 1996
182. Jarrett AF, Armstrong AA, Alexander E: Epidemiology of EBV and Hodgkin's lymphoma. Ann Oncol 7:S5, 1996 (suppl 4)
183. List AF, Greer JP, Cousar JB, Stein RS, Flexner JM, Sinangil F, Davis J, Volsky DJ, Purtilo DT: Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: Association with Epstein-Barr virus. Ann Intern Med 105:668, 1986
184. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, Come S, Silver B, Canellos GP, Tarbell NJ: Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: Long-term analysis of risk factors and outcome. Blood 87:3625, 1996
185. Young RC, Bookman MA, Longo DL: Late complications of Hodgkin's disease management. J Natl Cancer Inst Monogr 10:55, 1990
186. National Research Council: Health Effects of Exposure to Low Levels of Ionizing Radiation (BEIR V). Washington, DC, National Academy Press, 1990
187. United Nations Scientific Committee on the Effects of Atomic Radiation: Sources and effects of ionizing radiation: UNCLEAR 1994 Report to the General Assembly With Scientific Annexes. New York, NY, United Nations, 1994
188. Boice JD Jr: Carcinogenesis: A synopsis of human experience with external exposure in medicine. Health Phys 121:120, 1990
189. Kaldor JM, Day NE, Bell J, Clarke EA, Langmark F, Karjalainen S, Band P, Pedersen D, Choi W, Blair V, Henry-Amar M, Prior P. Assouline D, Pomp-Kirn V, Cartwright RA, Koch M, Arslan A, Fraser P, Sutcliffe SB, Host H, Hakama M, Stovall M: Lung cancer following Hodgkin's disease: A case-control study. Int J Cancer 52:677, 1992
190. Van Leeuwen FE, Klokman WJ, Stovall M, Hagenbeek A, van den Belt-Dusebout AW, Noyon R, Boice JD Jr, Burgers JMV, Somers R: Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 87:1530, 1995
191. Thomas D, Pagoda J, Langholz B, Mack W: Temporal modifiers of the radon-smoking interaction. Health Phys 67:675, 1994
192. Yao SX, Lubin JH, Qiao YL, Boice JD Jr, Li JY, Cai SK: Exposure to radon progeny, tobacco use and lung cancer in a case control study in southern China. Radiat Res 138:326, 1994
193. Sankila R, Garwicz S, Olsen JH, Dollner H, Hertz H, Kreuger A, Langmark F, Lanning M, Moller T, Tulinius H, for the Association of the Nordic Cancer Registies and the Nordic Society of Pediatric Hematology and Oncology: Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: A population-based cohort study of five Nordic countries. J Clin Oncol 14:1442, 1996
194. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin J-F, Willett CG: High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 79:1203, 1997
195. Pike MC, Krailo MD, Henderson BE, Casagrande JT, Hoel DG: 'Hormonal' risk factors, 'breast tissue age' and the age incidence of breast cancer. Nature 303:767, 1983
196. Boice JD Jr: Second cancer after Hodgkin's disease - The price of success? J Natl Cancer Inst 85:4, 1993
197. Zellmer DL, Wilson JF, Janjan NA: Dosimetry of the breast for determining carcinogenic risk of mantle irradiation. Int J Radiat Oncol Biol Phys 21:1343, 1991
198. Van Leeuwen FE, Stiggelbout AM, van den Belt-Dusebout AW, Noyon R, Eliel MR, van Kerkhoff EHM, Delemarre JFM, Somer R: Second cancers following testicular cancer. J Clin Oncol 11:415, 1993
199. Dietrich PY, Belleqih S, Henry-Amar M, Cosset JM, Hayat M: Linitis plastica after Hodgkin's disease. Lancet 342:57, 1993
200. Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS: Second cancers following pediatric Hodgkin's disease. J Clin Oncol 16:536, 1998
201. Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, Stone BJ, Green DM, Lombardi F, Newton W, Hoover RN, Fraumeni JF Jr, for the Late Effects Study Group: Bone sarcomas linked to radiation and chemotherapy of children. N Engl J Med 317:588, 1997
202. Tucker MA, Morris Jones PH, Boice JD Jr, Robison LL, Stone BJ, Stovall M, Jenkin RDT, Lubin JH, Baum ES, Siegel SE, Meadows AT, Hoover RN, Fraumeni JF Jr, for the Late Effects Study Group: Therapeutic radiation at a young age linked to secondary thyroid cancer. Cancer Res 51:2885, 1991
203. Hancock SL, Cox RS, McDougall IR: Thyroid diseases after treatment of Hodgkin's disease. N Engl J Med 325:599, 1991
204. Tucker MA, Misfeldt D, Coleman N, Clark WH Jr, Rosenberg SA: Cutaneous malignant melanoma after Hodgkin's disease. Ann Intern Med 102:37, 1985
205. Henry-Amar M, Joly F: Late complications after Hodgkin's disease. Ann Oncol 7:S115, 1996 (suppl 4)
206. Hancock SL, Tucker MA, Hoppe RT: Factors affecting late mortality from heart disease after treatment of Hodgkin's disease. JAMA 270:1949, 1993
207. Stewart JR, Fajardo LF: Radiation-induced heart disease: An update. Prog Cardiovasc Dis 27:173, 1984
208. Stewart JR, Fajardo LF, Gillette SM, Constine LS: Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31:1205, 1995
209. Boivin J-F, Hutchison GB, Lubin JH, Mauch P: Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 69:1241, 1992
210. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 11:1208, 1993
211. Hancock SL, Hoppe RT: Long-term complications of treatment and causes of mortality after Hodgkin's disease. Semin Radiat Oncol 6:225, 1996
212. Cosset JM, Henry-Amar M, Pellae-Cosset B, Carde P, Girinski T, Tubiana M, Hayat M: Pericarditis and myocardial infarctions after Hodgkin's disease therapy. Int J Radiat Oncol Biol Phys 21:447, 1991
213. Carlson RG, Mayfield WR, Norman S, Alexander JA: Radiation-associated valvular disease. Chest 99:538, 1991
214. Ginsberg SJ, Comis RL: The pulmonary toxicity of antineoplastic agents. Semin Oncol 9:34, 1982
215. Jules-Elysee K, White DA: Bleomycin-induced pulmonary toxicity. Clin Chest Med 11:1, 1990
216. Hirsch A, Els NV, Straus DJ, Gomez EG, Leung D, Portlock CS, Yahalom J: Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease. J Clin Oncol 14:1297, 1996
217. Jockovich M, Mendenhall NP, Sombeck MD, Talbert JL, Copeland EM III, Bland KI: Long-term complications of laparotomy in Hodgkin's disease. Ann Surg 219:615, 1994